Submit your resume today!
A newly developed molecular predictor has the potential to identify which patients with late-stage melanoma would be most likely to benefit from treatment with checkpoint inhibitors. Learn more via @CancerTherAdvsr: https://t.co/8J4G4o6uj6
.@CHI_Healthtech’s #Immunogenicity & #Bioassay Summit will bring scientists together to discuss the latest challenges facing the #bioanalytical industry. Interested in attending? Register & join our team in D.C.: https://t.co/uQ515KoZRP
As a Principal Investigator with BioAgilytix, you’ll have the opportunity to develop & validate #biomarker, cell-based, #immunogenicity, immuno- and enzymatic assays. #Apply today: https://t.co/vsBLPqbnqr #scientificcareers #biocareers
Join BioAgilytix’s Corinna Fiorotti, Ph.D. at APA 2018 for a presentation discussing development & validation of NAb #assays for #biosimilar Assessment”. Find additional session details here: https://t.co/oO36HGarCe
Fun team building event last week at Mission X Escape in Durham for Carston Bethers, Nikhil Soni, Jean and Ari Kennedy, Mark Bethers, Mili Tenga and Mark Nelson. Better luck next time!We had a fantastic time with this team this weekend! Thanks for playing, everyone!
As a Principal Investigator with BioAgilytix, you’ll have the opportunity to develop and validate biomarker, cell-based, immunogenicity, immuno- and enzymatic assays to support of innovative drug development projects. Apply today: bioagilytix.applicantpro.com/jobs/886757.html
We are excited to announce that our USA headquarters will be expanding again, this time by an additional 21,000+ square feet. The expansion will further grow capacity for all of our bioanalytical services and support our growing team: bit.ly/2NowB4c
Services
Platforms
